Genetics of Malignant Hyperthermia: A Brief Update
- PMID:33840940
- PMCID: PMC8022069
- DOI: 10.4103/joacp.JOACP_360_19
Genetics of Malignant Hyperthermia: A Brief Update
Abstract
Malignant hyperthermia susceptibility (MHS) and the associated condition malignant hyperthermia (MH) are rare but well-known disorders in the field of anesthesiology. MHS is usually determined by a history of a family member developing a positive episode during general anesthesia and then confirmed by an invasive caffeine halothane contracture test (CHCT). More recently, within the context of MH as a pharmacogenetic disorder, the question of whether or not MHS can be principally genetically determined is of high importance as knowledge of detailed pathogenesis may prevent against its largely invariable lethality if untreated. Thus, in this brief report, genetic terms, as well as updates in the genetics of MHS, will be reviewed in order to better understand both the condition and the current research.
Keywords: Genetic testing; MH susceptibility; malignant hyperthermia (MH).
Copyright: © 2021 Journal of Anaesthesiology Clinical Pharmacology.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
- Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.Serfas KD, Bose D, Patel L, Wrogemann K, Phillips MS, MacLennan DH, Greenberg CR.Serfas KD, et al.Anesthesiology. 1996 Feb;84(2):322-9. doi: 10.1097/00000542-199602000-00009.Anesthesiology. 1996.PMID:8602662
- Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.Sudo RT, Cunha LB, Carmo PL, Matos AR, Trachez MM, Cardoso LA, Aguiar MI, Abreu AV, Zapata-Sudo G.Sudo RT, et al.Braz J Med Biol Res. 2010 Jun;43(6):549-56. doi: 10.1590/s0100-879x2010007500045. Epub 2010 May 14.Braz J Med Biol Res. 2010.PMID:20464345
- Muscular body build and male sex are independently associated with malignant hyperthermia susceptibility.Butala B, Brandom B.Butala B, et al.Can J Anaesth. 2017 Apr;64(4):396-401. doi: 10.1007/s12630-017-0815-2. Epub 2017 Jan 6.Can J Anaesth. 2017.PMID:28063098English.
- Malignant hyperthermia: clinical and molecular aspects.Correia AC, Silva PC, da Silva BA.Correia AC, et al.Rev Bras Anestesiol. 2012 Nov-Dec;62(6):820-37. doi: 10.1016/S0034-7094(12)70182-4.Rev Bras Anestesiol. 2012.PMID:23176990Review.
- [Modern diagnostic approaches to malignant hyperthermia susceptibility].Kazantseva AA, Lebedinskiĭ KM.Kazantseva AA, et al.Anesteziol Reanimatol. 2014 Jul-Aug;59(4):64-8. doi: 10.18821/0201-7563-2014-59-4-64-68.Anesteziol Reanimatol. 2014.PMID:25549489Review.Russian.
Cited by
- A New Unified Theory of Trigger Point Formation: Failure of Pre- and Post-Synaptic Feedback Control Mechanisms.Gerwin RD.Gerwin RD.Int J Mol Sci. 2023 May 2;24(9):8142. doi: 10.3390/ijms24098142.Int J Mol Sci. 2023.PMID:37175845Free PMC article.
- Expanding Family Health History to Include Family Medication History.Haga SB, Orlando LA.Haga SB, et al.J Pers Med. 2023 Feb 25;13(3):410. doi: 10.3390/jpm13030410.J Pers Med. 2023.PMID:36983592Free PMC article.
- Hypertensive crisis precatheter ablation for resistant atrial fibrillation: a case of undiagnosed bilateral pheochromocytomas.Dhillon N, Baniak N, Nosib S.Dhillon N, et al.BMJ Case Rep. 2021 Oct 29;14(10):e244484. doi: 10.1136/bcr-2021-244484.BMJ Case Rep. 2021.PMID:34716146Free PMC article.
References
- Yano M, Yamamoto T, Ikeda Y, Matsuzaki M. Mechanisms of disease: Ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Pract Cardiovasc Med. 2006;3:43–52. - PubMed
- Robinson R, Anetseder M, Brancadoro V, van Broekhoven C, Carsana A, Censier K, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet. 2003;11:342–8. - PubMed
Related information
LinkOut - more resources
Full Text Sources